Management expects to deliver top line 6-month primary endpoint data from the REMAIN-1 pivotal study in early Q4 2026 and anticipates De Novo submission in late Q4 2026. The pivotal study is powered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results